Corticotropin Deficiency, Fasting
Conditions
Keywords
treatment, quality of life, hypoglycemia
Brief summary
Selected patients will be randomised to either hydrocortisone or prednisolone. Each treatment period is of 14 days. Abnormal clinical symptoms, blood glucose and quality of life will be monitored.
Detailed description
* Selection of the patients who meet the inclusion and non inclusion criteria. * Detailed explanations about the study to the patients. * Signature of the informed consent by the patients. * Randomisation of the patients by drawing lots into two groups; group AB who will receive treatment A during 14 days (period 1) then treatment B during 14 days (period 2) and group BA who will receive treatment B during 14 days (period 1) then treatment A during 14 days (period 2). * Each patient will receive a daily follow-up sheet, a quality of life questionnaire, a glucometer with test strips and the treatment in different bottles for each period of the study. * The daily follow-up sheet concerns habits during Ramadan (eating, sleeping), the occurrence of complications and blood glucose monitoring. Daily blood glucose monitoring is requested at midday, before dinner and if a malaise occurs. A detailed questionnaire on abnormal symptoms that might occur during fasting have to be fulfilled for each malaise. * Quality of life will be evaluated using AddiQol questionnaire translated in Tunisian dialect. Patients have to complete the questionnaire before the fasting month and at the end of each period of treatment. * Treatment is presented in the form of capsules with the same colour and size. Patients have to take one capsule at dinner and one capsule at pre-dawn meal. Patients will receive either hydrocortisone 15mg at pre-dawn meal and 5mg at dinner (sunset) (treatment A) or prednisolone 5mg at pre-dawn meal and a placebo (starch) at dinner (treatment B). * During the study, patients will be in regular phone contact with a responsible of the study for any information or problem. * At the end of the study, the completed follow-up sheets and questionnaires will be picked up.
Interventions
DRUGHydrocortisone
at a substitutive dosage
DRUGPrednisolone
at a substitutive dosage
Sponsors
University Tunis El Manar
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Caregiver)
Masking description
the treatment has been put in capsules with the same size and color
Intervention model description
crossover clinical trial
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Known corticotrope deficiency treated by 20mg hydrocortisone per day. * Age: 18-70 years * patients who are willing to fast Ramadan 2018 and who voluntary accept to participate in the study. Non inclusion criteria: Patients with either diabetes mellitus, hypertension, diabetes insipidus, severe organ damage (renal, cardiac, pulmonary, hepatic), neoplasia, psychiatric disease, epilepsy or pregnant or breast-feeding women.
Exclusion criteria
The occurrence of any of the non inclusion criteria during the study. The occurrence of a severe malaise.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Occurence of complications | during the fourteen days treatment period | fatigue, asthenia, symptoms of hypoglycemia, symptoms of dehydration, hypoglycemia on blood glucose monitoring |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| score of quality of life | during the fourteen days treatment period | using a questionnaire (AddiQol) |
Countries
Tunisia
Outcome results
None listed